BACKGROUND: Duodenal lesions (DLS) are common in patients with familial adenomatosis polyposis (FAP), and screening for duodenal adenocarcinoma (DA) is currently recommended. Endoscopic treatment of DLS is controversial. AIM: To report management and outcomes of endoscopic therapy for DLS in patients with FAP. METHODS: The records of patients with FAP who underwent endoscopic surveillance or therapy for DLS over a 15-year period were reviewed. Endoscopic intervention included endoscopic surveillance with biopsies, argon plasma coagulation (APC), endoscopic mucosal resection (EMR), EMR with APC, and ampullectomy. Main outcome measurements were recurrence and histology of DLS after endoscopic therapy, complications of endoscopic therapy, and need for duodenectomy. RESULTS: Seventy-one patients with FAP and DLS were identified from our endoscopy database as undergoing upper endoscopy for screening and/or surveillance (1995-2009). Mean follow up was 4.5 years (1-15 years). Seventy of the seventy-one (98.5%) patients had multiple flat DLS. Most of the patients were followed with yearly biopsies. APC was performed in 17 patients and EMR was performed in eight patients; in five of the eight EMR patients, APC was also performed to treat the edges of EMR site. During the follow up, 17/55 (31%) patients had histological progression (HP). HP was seen in 5/16 (31%) patients who underwent APC (one was lost to follow-up) and 12/40 (30%) patients followed with biopsies alone. Recurrence of lesions was noted in all patients. Two patients underwent duodenectomy. None of the patients developed DA during follow up. CONCLUSIONS: Endoscopic surveillance with directed endotherapy for DLS in FAP is feasible and safe when diligently performed.
BACKGROUND: Duodenal lesions (DLS) are common in patients with familial adenomatosis polyposis (FAP), and screening for duodenal adenocarcinoma (DA) is currently recommended. Endoscopic treatment of DLS is controversial. AIM: To report management and outcomes of endoscopic therapy for DLS in patients with FAP. METHODS: The records of patients with FAP who underwent endoscopic surveillance or therapy for DLS over a 15-year period were reviewed. Endoscopic intervention included endoscopic surveillance with biopsies, argon plasma coagulation (APC), endoscopic mucosal resection (EMR), EMR with APC, and ampullectomy. Main outcome measurements were recurrence and histology of DLS after endoscopic therapy, complications of endoscopic therapy, and need for duodenectomy. RESULTS: Seventy-one patients with FAP and DLS were identified from our endoscopy database as undergoing upper endoscopy for screening and/or surveillance (1995-2009). Mean follow up was 4.5 years (1-15 years). Seventy of the seventy-one (98.5%) patients had multiple flat DLS. Most of the patients were followed with yearly biopsies. APC was performed in 17 patients and EMR was performed in eight patients; in five of the eight EMR patients, APC was also performed to treat the edges of EMR site. During the follow up, 17/55 (31%) patients had histological progression (HP). HP was seen in 5/16 (31%) patients who underwent APC (one was lost to follow-up) and 12/40 (30%) patients followed with biopsies alone. Recurrence of lesions was noted in all patients. Two patients underwent duodenectomy. None of the patients developed DA during follow up. CONCLUSIONS: Endoscopic surveillance with directed endotherapy for DLS in FAP is feasible and safe when diligently performed.
Authors: Douglas G Adler; Waqar Qureshi; Raquel Davila; S Ian Gan; David Lichtenstein; Elizabeth Rajan; Bo Shen; Marc J Zuckerman; Robert D Fanelli; Trina Van Guilder; Todd H Baron Journal: Gastrointest Endosc Date: 2006-12 Impact factor: 9.427
Authors: M H Wallace; A Forbes; I G Beveridge; A D Spigelman; A Hewer; S Venitt; R K Phillips Journal: Dis Colon Rectum Date: 2001-11 Impact factor: 4.585
Authors: J Björk; H Akerbrant; L Iselius; A Bergman; Y Engwall; J Wahlström; T Martinsson; M Nordling; R Hultcrantz Journal: Gastroenterology Date: 2001-11 Impact factor: 22.682
Authors: Michael David Johnson; Richard Mackey; Nancy Brown; James Church; Carol Burke; R Matthew Walsh Journal: J Gastrointest Surg Date: 2010-02 Impact factor: 3.452
Authors: Ian D Norton; Christopher J Gostout; Todd H Baron; Alex Geller; Bret T Petersen; Maurits J Wiersema Journal: Gastrointest Endosc Date: 2002-08 Impact factor: 9.427
Authors: P Mlkvy; H Messmann; H Debinski; J Regula; M Conio; A MacRobert; A Spigelman; R Phillips; S G Bown Journal: Eur J Cancer Date: 1995 Jul-Aug Impact factor: 9.162
Authors: Wim Laleman; Annelies Verreth; Baki Topal; Raymond Aerts; Mina Komuta; Tania Roskams; Schalk Van der Merwe; David Cassiman; Frederik Nevens; Chris Verslype; Werner Van Steenbergen Journal: Surg Endosc Date: 2013-05-25 Impact factor: 4.584
Authors: Fábio Guilherme Campos; Marianny Sulbaran; Adriana Vaz Safatle-Ribeiro; Carlos Augusto Real Martinez Journal: World J Gastrointest Endosc Date: 2015-08-10
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: E Soons; T M Bisseling; M C A van Kouwen; G Möslein; P D Siersema Journal: United European Gastroenterol J Date: 2021-05-07 Impact factor: 4.623
Authors: M Sulbaran; F G Campos; U Ribeiro; H S Kishi; P Sakai; E G H de Moura; L Bustamante-López; M Tomitão; S C Nahas; I Cecconello; A V Safatle-Ribeiro Journal: Endosc Int Open Date: 2018-04-18